Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079165 | 1.00 | MAPT (0.68) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL29951439 | 1.00 | MAPT (0.68) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL10384632 | 0.85 | MAPT (0.65) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL20517908 | 0.84 | MAPT (0.64) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL3462948 | 0.82 | MAPT (0.61) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL30478655 | 0.82 | MAPT (0.61) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL2491340 | 0.82 | MAPT (0.61) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL981600 | 0.81 | MAPT (1.00) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL12948682 | 0.81 | MAPT (1.00) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL11787354 | 0.80 | MAPT (0.59) | MAPTRAB9AMAPK1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109312247-A | Mercaptopyrrole Derivatives as Lubricant Additives | 路博润公司 | 2019-02-05 | — | — | CN | claimed |
| US-10167501-B2 | Methods and apparatus for quantification of nucleic acid amplification by monitoring impedances | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-01-01 | — | — | US | claimed |
| CN-108200770-A | Pyrrole derivatives as lubricant additives | 路博润公司 | 2018-06-22 | — | — | CN | claimed |
| CN-108138070-A | Pyrrole derivatives as lubricant additives | 路博润公司 | 2018-06-08 | — | — | CN | claimed |
| US-20160046977-A1 | Methods and Apparatus for Amplifying Nucleic Acids | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | US | claimed |
| US-20140086977-A1 | TIGHT JUNCTIONS MODULATORS | THE UNIVERSITY OF MANCHESTER (GB) | 2014-03-27 | — | — | US | claimed |
| EP-2691090-A2 | TIGHT JUNCTIONS MODULATORS | The University Of Manchester (GB) | 2014-02-05 | — | — | EP | claimed |
| WO-2012131341-A2 | TIGHT JUNCTIONS MODULATORS | THE UNIVERSITY OF MANCHESTER (GB) | 2012-10-04 | — | — | WO | claimed |
| EP-0802782-B1 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL MYERS SQUIBB CO (US) | 2003-02-05 | — | — | EP | claimed |
| EP-3337882-B1 | AZOLE DERIVATIVES AS LUBRICATING ADDITIVES | LUBRIZOL CORP (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024094962-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| CN-114122398-B | Integrated conductive adhesive and preparation method and application thereof | 西安交通大学 | 2023-12-19 | — | — | CN | disclosed |
| EP-3969450-B1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SUZHOU FOUR HEALTH PHARMACEUTICALS CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2003000915-A1 | METHOD FOR PRODUCING L-AMINO ACIDS | SHOWA DENKO K.K. (JP) | 2003-01-03 | — | — | WO | disclosed |
| EP-0274825-B1 | Indole derivatives and their uses in agriculture | SYNGENTA LTD (GB) | 2002-09-11 | — | — | EP | disclosed |
| EP-0612525-B1 | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL MYERS SQUIBB CO (US) | 2001-09-19 | — | — | EP | disclosed |
| US-5843979-A | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0273572-B1 | Pyrrole derivatives and their use in agriculture | ZENECA LTD (GB) | 1996-01-24 | — | — | EP | disclosed |
| EP-0612525-A1 | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086977-A1 | TIGHT JUNCTIONS MODULATORS | DSG1, KRT18, STOM | MAPT 541/4885RAB9A 1534/4885MAPK1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.